Europe contemplates unified drug prices to counter US pressure to spend more. Experts are guarded in their expectations.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

Formulation differentiates therapies in crowded markets by improving adherence, tolerability, convenience, and delivery efficiency.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

Monod Bio and SignalChem Biotech Inc announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies.

The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials, the Asia-Pacific (APAC) region is now driving innovation ...

Analysts are heralding functional cures like Hibsago in chronic hepatitis B as the next frontier in treatment for patients.

The EC has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart for the treatment of Cushing’s syndrome of endogenous origin.

Ultragenyx Pharmaceutical has received accelerated approval from the FDA for its gene therapy, Genglycos, to treat GSDIa.